查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2045172

基於價值的腫瘤治療市場：策略性洞察與預測（2026-2031 年）

Value-Based Oncology Care Market - Strategic Insights and Forecasts (2026-2031)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計以價值為基礎的腫瘤護理市場將從 2026 年的 205 億美元成長到 2031 年的 280 億美元，複合年成長率為 6.4%。

隨著醫療服務提供者、保險公司、製藥公司和政策制定者加速從傳統的計量型模式向以價值主導的腫瘤治療框架轉型，全球基於價值的腫瘤治療市場正經歷著重大變革。基於價值的腫瘤治療致力於透過實證治療路徑、基於結果的補償機制、個人化護理管理以及以結果為導向的醫療服務體系，來改善患者預後、提升醫療品質、最佳化護理協調並提高成本效益。癌症治療帶來的日益沉重的經濟負擔，正加速推動對能夠兼顧臨床療效和成本效益的永續腫瘤治療模式的需求。

全球癌症負擔日益加重，仍是市場成長的主要驅動力。乳癌、肺癌、大腸癌、攝護腺癌、骨髓惡性腫瘤和其他癌症的發生率不斷上升，持續對全球醫療保健系統造成巨大壓力。人口老化、久坐的生活方式、肥胖症的流行、環境風險因素以及遺傳易感性等因素，都導致了癌症發病率的上升以及對長期治療需求的增加。醫療服務提供者和保險公司正日益尋求既能改善患者預後又能控制不斷上漲的醫療成本的、具有成本效益的癌症管理策略。

先進癌症治療成本的不斷攀升正顯著加速市場發展。免疫療法、CAR-T細胞療法、放射性配體療法、生物目標、基因組檢測和個人化醫療等方法雖然改善了臨床療效，但也大幅增加了治療成本。傳統的計量型補償系統往往更注重治療次數而非病患療效。基於價值的腫瘤治療模式透過將補償與治療品質、患者滿意度、存活率和醫療效率掛鉤，有效應對了這項挑戰。

醫療系統在癌症治療領域正日益採用替代支付模式（APM）和基於結果的補償框架。諸如打包支付、按病程付費、共用收益模式、責任醫療組織（ACO）和風險分擔協議等項目在癌症治療網路中已變得普遍。這些模式鼓勵醫療服務提供者最佳化護理協調，減少不必要的住院治療，最大限度地減少不必要的干涉措施，並提高長期存活率。

精準醫療和實證腫瘤治療方案的推廣是推動市場發展的另一個主要因素。臨床決策支援系統、基因組分析、生物標記檢測和人工智慧驅動的治療分析，使腫瘤科醫師能夠根據患者特定的分子特徵和預測的治療方法反應，制定個人化的治療方案。由NCCN等機構支持的實證治療方案，正日益融入腫瘤診療流程，以規範醫療品質並最佳化醫療資源的利用。

此外，醫療資訊技術和數位化腫瘤基礎設施的快速發展也對市場產生了積極影響。電子健康記錄、人工智慧驅動的預測分析、遠端患者監護系統、數位化症狀追蹤和人群健康管理平台正在改善醫療協調，並實現數據驅動的腫瘤管理。醫療機構擴大利用真實世界數據（REW）和臨床分析來評估治療效果、患者用藥依從性和長期照護結果。

隨著腫瘤治療重心轉向以患者為中心的模式，治療模式正經歷重大變化。在以價值觀為導向的腫瘤治療框架下，生活品質、患者參與、心理健康支持、復健期護理、症狀管理以及多學科協作護理至關重要。腫瘤科診療實踐正日益提供導航服務、心理社會支持、營養諮詢以及全天候患者服務項目，以提高治療依從性並減少不必要的急診就診。

在以價值為導向的腫瘤治療生態系統中，支付方和醫療服務提供者之間的合作變得日益重要。保險公司、醫療管理機構、腫瘤網路和醫療服務提供者正攜手合作，建立標準化的治療路徑、療效評估框架和報銷最佳化策略。製藥公司也參與與治療效果和患者預後相關的價值導向合約。

區域癌症診療模式的廣泛應用是影響市場的另一個重要趨勢。區域癌症網路日益注重在患者居住附近提供高品質的癌症診療服務，同時減少治療片段化和降低醫療成本。由數位健康平台和即時分析支援的整合式癌症治療路徑正在提高營運效率並實現治療標準化。

人工智慧、機器學習、醫療分析和預測建模的進步顯著提升了基於價值的腫瘤管理能力。人工智慧驅動的系統能夠實現風險分層、治療最佳化、病患監測和預測性醫療服務利用。預測分析有助於醫療服務提供者識別高風險患者、改善護理協調並減少可預防的治療併發症。

北美目前在以價值為導向的腫瘤治療市場中處於領先地位，這得益於其先進的醫療基礎設施、癌症治療技術的廣泛應用、保險公司與醫療服務提供者之間的緊密合作，以及美國醫療保險和醫療補助服務中心（CMS）主導的替代支付模式的日益普及。歐洲也是一個重要的市場，這得益於全民健保、成本控制措施和實證腫瘤學框架。亞太地區預計將經歷快速成長，這主要歸功於癌症發病率的上升、醫療保健的現代化、保險覆蓋範圍的擴大，以及中國、日本、印度和韓國等國家對數位醫療技術的日益普及。

儘管成長前景強勁，但該市場仍面臨諸多挑戰，包括報銷機制複雜、互通性有限、監管不確定性、醫療服務提供者不願分擔財務風險以及標準化療效評估等問題。然而，醫療分析、精準腫瘤學、數位基礎設施以及支付方與醫療服務提供者之間合作的持續進步，有望為基於價值的腫瘤治療市場創造顯著的長期成長機會。

市場促進因素

癌症治療費用不斷上漲

免疫療法、標靶治療、基因組檢測和個人化癌症治療等相關成本的不斷上漲，是推動以價值為導向的腫瘤醫療市場發展的關鍵因素之一。醫療系統日益需要永續的報銷模式，以在提高醫療品質的同時減少不必要的支出。

以價值觀為導向的醫療保健框架有助於最佳化治療效率和醫療資源利用。

替代支付模式的普及

醫療服務提供者和保險公司在癌症治療中擴大採用打包支付、收入分成計劃、責任醫療組織 (ACO) 和按病程付費的報銷框架。

替代支付模式促進協調的醫療保健服務和以治療結果為中心的策略。

精準腫瘤學的擴展

基因組分析、生物標記檢測、分子診斷和人工智慧驅動的治療分析正在提升治療的個人化程度和實證臨床決策水平。精準腫瘤學框架有助於改善患者預後並提高醫療效率。

循證護理路徑正日益融入腫瘤治療的工作流程中。

越來越重視以病人為中心的護理

在醫療保健系統中，生活品質管理、倖存者關懷、患者參與以及協調的多學科腫瘤支持服務的重要性日益凸顯。以病人為中心的照護模式能夠提高治療順從性和病人滿意度。

綜合支持性護理計劃正成為以價值觀為基礎的腫瘤學框架中的重要組成部分。

醫療分析和數位基礎設施的進步

人工智慧驅動的分析、電子健康記錄、預測建模和遠端患者監護技術正在提升腫瘤治療領域的協作效率和營運效率。醫療機構越來越依賴真實世界數據和數位健康平台進行績效評估。

數位化轉型持續提升數據驅動的腫瘤管理能力。

市場限制因素

報銷模式複雜

市場限制因素之一是基於價值的報銷框架、風險分擔協議和績效評估體系的複雜性。醫療服務提供者在實施過程中可能會面臨行政負擔和財務不確定性。

標準化方面的挑戰持續影響還款流程的最佳化。

互通性和數據整合面臨的挑戰

醫療保健系統通常依賴分散的數位基礎設施，涉及多個電子健康記錄系統和數據平台。缺乏互通性會阻礙有效的護理協調和治療結果的追蹤。

整合醫療數據管理仍然是一項重大的營運挑戰。

法規和合規方面的不確定性

以價值為導向的癌症治療計畫必須遵守不斷變化的醫療保健法規、報銷政策、病患隱私標準和報告要求。不同醫療保健系統之間的法規差異會使實施變得複雜。

醫療服務提供者不斷調整自身以適應不斷變化的報銷和合規框架。

醫療服務提供者對財務風險分擔的抗拒情緒

由於治療結果衡量方面的操作複雜性和不確定性，一些腫瘤醫療保健提供者可能對基於結果的補償和財務風險分擔模式仍持謹慎態度。

從計量型的補償制度過渡到組織轉型需要組織變革。

科技領域洞察

基於價值的腫瘤治療市場按支付模式、技術、癌症類型、最終用戶和地區進行細分。按支付模式分類，市場包括打包支付、責任醫療組織 (ACO)、共用節約計畫、績效補償模式和按病程付費方案。由於打包支付在整個腫瘤治療路徑中的應用日益廣泛，目前其市場佔有率較大。

支付者和醫療服務提供者之間合作舉措的日益增多，正在加速共用利益、責任制醫療框架的發展。

按技術細分，市場涵蓋電子健康記錄、臨床決策支援系統、預測分析、人工智慧驅動的醫療平台、遠端患者監護以及腫瘤診療路徑管理系統。由於電子健康記錄和臨床分析平台在協調醫療服務和監測績效方面得到廣泛應用，目前它們佔據市場主導地位。

由於對癌症治療即時洞察的需求不斷成長，人工智慧驅動的預測分析和數位症狀管理系統正在迅速發展。

依癌症類型分類，市場涵蓋乳癌、肺癌、大腸癌、攝護腺癌和骨髓惡性腫瘤。由於乳癌發生率高且實證治療方案已廣泛應用，目前乳癌佔據了主要的市場佔有率。

此外，由於肺癌和骨髓惡性腫瘤治療的複雜性和醫療成本高昂，基於價值的醫療策略正日益被採用。

從終端用戶角度來看，市場包括醫院、腫瘤診所、區域癌症網路、保險公司、醫療管理機構和專科癌症中心。目前，醫院和腫瘤網路憑藉其整合的多學科治療基礎設施和報銷管理能力，在市場中佔據主導地位。

由於人們對提供以社區為基礎、經濟有效的癌症治療的興趣日益濃厚，區域癌症網路不斷擴大。

從區域來看，北美目前佔據市場主導地位，這得益於其高昂的醫療費用支出、先進的腫瘤治療基礎設施以及在醫療保險和醫療補助服務中心 (CMS) 的支持下，替代支付模式的日益普及。歐洲是另一個主要市場，這得益於其在醫療保健現代化和提高成本效益方面所做的努力。

由於癌症發病率上升、醫療保健數位化以及保險覆蓋範圍擴大，亞太地區預計將經歷快速成長。

競爭與策略展望

以價值為導向的腫瘤治療市場競爭異常激烈，參與者包括醫療科技公司、腫瘤網路、製藥公司、醫療管理機構和醫療分析提供者。主要市場參與企業包括 McKesson Corporation、Optum, Inc.、IBM Corporation、Flatiron Health、美國腫瘤網路 (The US Oncology Network)、Cigna Group、Elevance Health, Inc.、CVS Health Corporation、Oracle Health 和 OneOncology。

領導企業正日益重視整合數位化腫瘤基礎設施、預測分析、護理協調平台和實證治療路徑，以鞏固其市場地位。整個產業對人工智慧驅動的臨床決策支援系統、人群健康分析和遠端患者監護技術的投資正在加速成長。

麥克森公司和美國腫瘤網路持續拓展其以價值為導向的腫瘤解決方案，包括整合品質報告、治療路徑管理和臨床分析。醫療科技公司正日益加強與腫瘤醫療機構和保險公司的合作，以提高互通性和醫療效率。

市場越來越關注真實世界數據（REW）的生成、患者導航服務、個人化腫瘤治療路徑以及整合式支援護理框架。能夠降低醫療成本、改善治療效果並增強患者參與度的機構有望提升其長期市場競爭力。

結論

由於癌症治療成本飆升、替代支付模式的日益普及以及對以患者為中心的醫療保健服務的日益重視，全球基於價值的腫瘤護理市場預計將大幅成長。

精準腫瘤學、醫學分析、人工智慧決策支援系統和數位化護理協調技術的進步正在從根本上改變腫瘤治療的框架。醫療保健系統越來越重視以結果為基礎的報銷模式，這種模式既能提高治療質量，又能降低整體醫療成本。

該市場持續面臨許多挑戰，例如報銷機制的複雜性、互通性有限、監管的不確定性以及醫療服務提供者的適應能力。然而，醫療保健的持續現代化、循證腫瘤治療路徑的擴展以及支付方與醫療服務提供者之間合作的加強，預計將為基於價值的腫瘤治療市場創造顯著的長期成長機會。

本報告的主要益處

  • 深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業領域進行詳細的市場洞察。
  • 競爭格局：了解主要參與者的策略舉措，並確定最佳的市場進入方式。
  • 市場促進因素和未來趨勢：我們將評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策以開發新的收入來源。
  • 適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

我們的報告有哪些用途範例？

產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

報告範圍

  • 歷史資料為 2021 年至 2024 年，基準年為 2025 年，預測期間為 2026 年至 2031 年。
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略、市場佔有率評估、貿易分析
  • 細分市場和區域銷售成長及預測評估
  • 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章執行摘要

  • 市場概覽
  • 重點
  • 腫瘤學中的價值醫療模式概述
  • 主要市場趨勢
  • 分析師建議

第2章 疾病與流行病學分析

  • 全球癌症負擔概述
    • 按類型分類的癌症發生率和盛行率
    • 死亡率趨勢與存活率
  • 按主要適應症分類的流行病學
    • 乳癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
    • 骨髓惡性腫瘤
  • 癌症治療帶來的經濟負擔
    • 直接醫療費用
    • 間接成本和生產力下降
  • 建立以價值為導向的腫瘤護理模式的必要性

第3章：基於價值的腫瘤護理市場的市場動態

  • 市場定義和範圍
  • 市場促進因素
    • 癌症發生率和治療費用增加
    • 從計量型向基於價值的模式過渡
    • 擴大以績效為基礎的薪酬體系
  • 市場限制因素
    • 結果測量的複雜性
    • 數據整合和互通性挑戰
    • 價值指標標準化進程的延遲
  • 市場機遇
    • 真實世界數據（RWE）的整合
    • 數位健康和​​腫瘤數據平台
    • 擴充捆綁支付模式
  • 市場挑戰
    • 醫療服務提供者的抵制和工作流程中斷
    • 監管和定價方面的不確定性

第4章 商業和市場進入

  • 腫瘤領域報銷模式概述
  • 腫瘤學中基於價值的支付模式
    • 綜合支付
    • 腫瘤護理模式（OCM）及其後續模式
    • 責任醫療組織（ACO）
    • 績效合約
  • 基於價值的腫瘤學定價策略
  • 支付者/提供者的角色
  • 市場進入決策中的真實數據
  • 腫瘤學健康技術評估 (HTA)

第5章：創新與通路的現狀

  • 創新在基於價值的腫瘤治療中的作用
  • 依治療方法概述管道
    • 免疫療法（查核點抑制劑、CAR-T療法）
    • 標靶治療
    • 放射性藥物
  • 依開發階段進行管道分析
    • 第一階段
    • 第二階段
    • 第三階段
  • 作用機制的發展趨勢
  • 伴隨診斷整合
  • 支持以價值為導向的醫療保健的數位健康創新
    • 臨床決策支援系統
    • 遠端患者監護
    • 人工智慧在癌症治療路徑中的應用

第6章 當前治療狀況

  • 不同類型癌症的標準治療方法
  • 精準醫療在腫瘤學中的作用
  • 整合多學科協作護理模式
  • 生物標記和伴隨診斷的應用
  • 基於價值的治療路徑模型
  • 癌症治療結果的測量
    • 臨床結果
    • 患者報告結局（PROs）
    • 品質調整生命年（QALY）

第7章：基於價值的腫瘤護理市場規模及預測

  • 全球市場規模（歷史數據）
  • 市場預測
  • 成長率分析（複合年均成長率）
  • 主要細分市場的市場佔有率
  • 情境分析（樂觀情境、基本情境、保守情境）

第8章：基於價值的腫瘤護理市場細分

  • 按治療類型
    • 化療
    • 標靶治療
    • 免疫療法
    • 聯合治療
  • 適應症
    • 乳癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
    • 骨髓惡性腫瘤
  • 透過行政途徑
    • 口服
    • 靜脈
    • 皮下
  • 最終用戶
    • 醫院
    • 腫瘤診所
    • 門診手術中心
  • 透過分銷管道
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第9章 區域分析（區域層級）

  • 北美洲
    • 市場規模和成長
    • 主要需求因素
    • 法規概述
    • 競爭強度
  • 歐洲
    • 市場規模和成長
    • 主要需求因素
    • 法規概述
    • 競爭強度
  • 亞太地區
    • 市場規模和成長
    • 主要需求因素
    • 法規概述
    • 競爭強度
  • 拉丁美洲
    • 市場規模和成長
    • 主要需求因素
    • 法規概述
    • 競爭強度
  • 中東和非洲
    • 市場規模和成長
    • 主要需求因素
    • 法規概述
    • 競爭強度

第10章 主要國家分析

  • 美國
    • 市場規模
    • 癌症流行病學
    • 法律規範（FDA）
    • 贖回環境
    • 主要公司及其產品部署狀況
  • 加拿大
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 德國
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 英國
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 法國
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 義大利
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 西班牙
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 中國
    • 市場規模
    • 流行病學
    • 法律規範（NMPA）
    • 贖回
    • 大公司
  • 日本
    • 市場規模
    • 流行病學
    • 法律規範（PMDA）
    • 贖回
    • 大公司
  • 印度
    • 市場規模
    • 流行病學
    • 法律規範（CDSCO）
    • 贖回
    • 大公司
  • 韓國
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 澳洲
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 巴西
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 墨西哥
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 沙烏地阿拉伯
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司
  • 南非
    • 市場規模
    • 流行病學
    • 法律規範
    • 贖回
    • 大公司

第11章：監理情勢與政策趨勢

  • 美國（FDA）
    • 基於價值的醫療保健政策
    • 專門針對癌症治療的支付模式
  • 歐洲（在EMA和MDR框架內）
    • 人力稅務管理局 (HTA) 和價格法規
    • 基於價值的合約
  • 日本（PMDA）
    • 定價和兌換政策
  • 印度（CDSCO）
    • 價格管制和准入計劃
  • 中國（NMPA）
    • 基於數量的採購和定價
  • 全球基於價值的腫瘤學趨勢

第12章 競爭格局

  • 市場結構分析
  • 關鍵策略舉措
    • 夥伴關係與合作
    • 併購
    • 基於價值的合約協議
  • 市佔率分析（僅供參考）
  • 競爭基準

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Johnson & Johnson

13.8 安進

    • 核准產品
    • 關鍵指標
    • 管道概覽

13.9 吉利德科學公司

    • 核准產品
    • 關鍵指標
    • 管道概覽

第14章：未來展望

  • 價值驅動型腫瘤學模式的演變
  • 人工智慧與巨量資料融合
  • 向個人化醫療和結果導向醫療轉型
  • 長期市場機遇
  • 策略建議

第15章：調查方法

  • 調查設計
  • 數據來源
  • 市場估算方法
  • 預測性調查方法
  • 先決條件和限制
簡介目錄
Product Code: KSI-008616

The Value-Based Oncology Care market is forecast to grow at a CAGR of 6.4%, reaching USD 28.0 billion in 2031 from USD 20.5 billion in 2026.

The global value-based oncology care market is undergoing significant transformation as healthcare providers, payers, pharmaceutical companies, and policymakers increasingly shift from traditional fee-for-service reimbursement models toward value-driven cancer care frameworks. Value-based oncology care focuses on improving patient outcomes, treatment quality, care coordination, and cost efficiency through evidence-based treatment pathways, performance-based reimbursement, personalized care management, and outcome-focused healthcare delivery systems. The growing financial burden associated with cancer treatment is accelerating demand for sustainable oncology care models capable of balancing clinical effectiveness and healthcare affordability.

The increasing global cancer burden remains one of the primary drivers supporting market growth. Rising incidences of breast cancer, lung cancer, colorectal cancer, prostate cancer, hematologic malignancies, and other oncology conditions continue increasing pressure on healthcare systems worldwide. Aging populations, sedentary lifestyles, obesity prevalence, environmental risk factors, and genetic predisposition contribute to increasing cancer incidence and long-term treatment demand. Healthcare providers and payers increasingly seek cost-effective oncology management strategies capable of improving patient outcomes while controlling escalating healthcare expenditures.

The growing cost of advanced oncology therapies is significantly accelerating market development. Immunotherapies, CAR-T cell therapies, radioligand therapies, targeted biologics, genomic testing, and personalized medicine approaches have improved clinical outcomes but substantially increased treatment costs. Traditional fee-for-service reimbursement systems often incentivize treatment volume rather than patient outcomes. Value-based oncology care models address this challenge by linking reimbursement to treatment quality, patient satisfaction, survival outcomes, and healthcare efficiency.

Healthcare systems are increasingly adopting alternative payment models (APMs) and performance-based reimbursement frameworks within oncology care. Programs such as bundled payments, episode-based reimbursement, shared savings models, accountable care organizations, and risk-sharing agreements are becoming more common across oncology networks. These models encourage providers to optimize care coordination, reduce avoidable hospitalizations, minimize unnecessary interventions, and improve long-term survivorship outcomes.

The expansion of precision medicine and evidence-based oncology pathways is another major factor shaping the market. Clinical decision support systems, genomic profiling, biomarker testing, and AI-powered treatment analytics enable oncologists to personalize therapy selection based on patient-specific molecular characteristics and predicted treatment response. Evidence-based treatment pathways supported by organizations such as NCCN are increasingly integrated into oncology workflows to standardize care quality and optimize healthcare resource utilization.

The market is also benefiting from rapid advancements in healthcare information technology and digital oncology infrastructure. Electronic health records, AI-powered predictive analytics, remote patient monitoring systems, digital symptom tracking, and population health management platforms are improving care coordination and enabling data-driven oncology management. Healthcare organizations increasingly utilize real-world evidence and clinical analytics to assess treatment effectiveness, patient adherence, and long-term care outcomes.

The increasing focus on patient-centered oncology care is significantly transforming treatment delivery models. Value-based oncology frameworks prioritize quality-of-life improvement, patient engagement, mental health support, survivorship care, symptom management, and coordinated multidisciplinary care. Oncology practices increasingly provide navigation services, psychosocial support, nutritional counseling, and 24/7 patient access programs to improve treatment adherence and reduce avoidable emergency care utilization.

Payer-provider collaboration is becoming increasingly important within value-based oncology ecosystems. Insurance companies, managed care organizations, oncology networks, and healthcare providers are collaborating to establish standardized treatment pathways, outcome measurement frameworks, and reimbursement optimization strategies. Pharmaceutical companies are also participating in value-based agreements tied to therapeutic effectiveness and patient outcomes.

The growing adoption of community oncology care models is another important trend influencing the market. Community oncology networks increasingly focus on delivering high-quality cancer care close to patient homes while reducing treatment fragmentation and healthcare costs. Integrated oncology care pathways supported by digital health platforms and real-time analytics are improving operational efficiency and treatment standardization.

Technological advancements in artificial intelligence, machine learning, healthcare analytics, and predictive modeling are significantly improving value-based oncology management capabilities. AI-powered systems enable risk stratification, treatment optimization, patient monitoring, and healthcare utilization forecasting. Predictive analytics help healthcare providers identify high-risk patients, improve care coordination, and reduce avoidable treatment complications.

North America currently dominates the value-based oncology care market due to advanced healthcare infrastructure, widespread oncology technology adoption, strong payer-provider integration, and increasing implementation of CMS-supported alternative payment models. Europe also represents a significant market supported by universal healthcare systems, cost-containment initiatives, and evidence-based oncology frameworks. Asia Pacific is expected to witness rapid growth due to increasing cancer prevalence, healthcare modernization, expanding insurance coverage, and rising adoption of digital healthcare technologies across countries such as China, Japan, India, and South Korea.

Despite strong growth prospects, the market faces challenges related to reimbursement complexity, interoperability limitations, regulatory uncertainty, provider resistance to financial risk-sharing, and difficulties associated with standardized outcome measurement. However, ongoing advancements in healthcare analytics, precision oncology, digital infrastructure, and payer-provider collaboration are expected to create substantial long-term growth opportunities for the value-based oncology care market.

Market Drivers

Rising Cost of Cancer Treatment

The increasing cost associated with immunotherapy, targeted therapies, genomic testing, and personalized oncology treatments is one of the primary drivers supporting the value-based oncology care market. Healthcare systems increasingly seek sustainable reimbursement models capable of improving care quality while reducing unnecessary expenditure.

Value-based care frameworks help optimize treatment efficiency and healthcare resource utilization.

Growing Adoption of Alternative Payment Models

Healthcare providers and payers are increasingly implementing bundled payments, shared savings programs, accountable care organizations, and episode-based reimbursement frameworks within oncology care delivery.

Alternative payment models encourage coordinated care delivery and outcome-focused treatment strategies.

Expansion of Precision Oncology

Genomic profiling, biomarker testing, molecular diagnostics, and AI-powered treatment analytics are improving therapy personalization and evidence-based clinical decision-making. Precision oncology frameworks support better patient outcomes and healthcare efficiency.

Evidence-based care pathways are increasingly integrated into oncology treatment workflows.

Increasing Focus on Patient-Centered Care

Healthcare systems increasingly prioritize quality-of-life management, survivorship care, patient engagement, and coordinated multidisciplinary oncology support services. Patient-centered care models improve treatment adherence and patient satisfaction.

Integrated supportive care programs are becoming essential components of value-based oncology frameworks.

Advancements in Healthcare Analytics and Digital Infrastructure

AI-powered analytics, electronic health records, predictive modeling, and remote patient monitoring technologies are improving oncology care coordination and operational efficiency. Healthcare organizations increasingly rely on real-world evidence and digital health platforms for performance evaluation.

Digital transformation continues strengthening data-driven oncology management capabilities.

Market Restraints

Complexity of Reimbursement Models

One of the major restraints affecting the market is the complexity associated with value-based reimbursement frameworks, risk-sharing agreements, and performance measurement systems. Providers may face administrative burden and financial uncertainty during implementation.

Standardization challenges continue affecting reimbursement optimization.

Interoperability and Data Integration Challenges

Healthcare systems often operate across fragmented digital infrastructures involving multiple electronic health record systems and data platforms. Limited interoperability may restrict effective care coordination and outcome tracking.

Integrated healthcare data management remains a significant operational challenge.

Regulatory and Compliance Uncertainty

Value-based oncology care programs must comply with evolving healthcare regulations, reimbursement policies, patient privacy standards, and reporting requirements. Regulatory variability across healthcare systems may complicate implementation.

Healthcare providers continue adapting to changing reimbursement and compliance frameworks.

Provider Resistance to Financial Risk-Sharing

Some oncology providers may remain cautious regarding performance-based reimbursement and financial risk-sharing models because of operational complexity and uncertainty surrounding outcome measurement.

Transitioning from fee-for-service systems requires significant organizational transformation.

Technology and Segment Insights

The value-based oncology care market is segmented by payment model, technology, cancer type, end-user, and geography. By payment model, the market includes bundled payments, accountable care organizations, shared savings programs, pay-for-performance models, and episode-based reimbursement systems. Bundled payment models currently account for a substantial market share due to increasing adoption across oncology treatment pathways.

Shared savings and accountable care frameworks are witnessing increasing growth because of rising payer-provider collaboration initiatives.

Based on technology, the market includes electronic health records, clinical decision support systems, predictive analytics, AI-powered healthcare platforms, remote patient monitoring, and oncology pathway management systems. Electronic health records and clinical analytics platforms currently dominate the market due to extensive utilization in care coordination and performance monitoring.

AI-powered predictive analytics and digital symptom management systems are expanding rapidly because of increasing demand for real-time oncology insights.

By cancer type, the market includes breast cancer, lung cancer, colorectal cancer, prostate cancer, hematologic malignancies, and others. Breast cancer currently represents a major market segment because of high disease prevalence and extensive implementation of evidence-based treatment pathways.

Lung cancer and hematologic malignancies are also witnessing substantial adoption of value-based care strategies due to high treatment complexity and healthcare expenditure.

Based on end-user, the market includes hospitals, oncology clinics, community oncology networks, payers, managed care organizations, and specialty cancer centers. Hospitals and oncology networks currently dominate the market because of integrated multidisciplinary treatment infrastructure and reimbursement management capabilities.

Community oncology networks are increasingly expanding because of growing focus on localized, cost-efficient cancer care delivery.

Regionally, North America currently dominates the market due to strong healthcare expenditure, advanced oncology infrastructure, and increasing adoption of CMS-supported alternative payment models. Europe represents another major market supported by healthcare modernization and cost-efficiency initiatives.

Asia Pacific is expected to witness rapid growth due to increasing cancer burden, healthcare digitalization, and expanding insurance coverage frameworks.

Competitive and Strategic Outlook

The value-based oncology care market is highly competitive and characterized by the presence of healthcare technology companies, oncology networks, pharmaceutical firms, managed care organizations, and healthcare analytics providers. Key market participants include McKesson Corporation, Optum, Inc., IBM Corporation, Flatiron Health, The US Oncology Network, Cigna Group, Elevance Health, Inc., CVS Health Corporation, Oracle Health, and OneOncology.

Leading organizations are increasingly focusing on digital oncology infrastructure, predictive analytics, care coordination platforms, and evidence-based treatment pathway integration to strengthen market positioning. Investments in AI-powered clinical decision support systems, population health analytics, and remote patient monitoring technologies are accelerating across the industry.

McKesson and The US Oncology Network continue expanding value-based oncology solutions involving quality reporting, pathway management, and clinical analytics integration. Healthcare technology companies increasingly collaborate with oncology providers and payers to improve interoperability and healthcare efficiency.

The market is witnessing increasing focus on real-world evidence generation, patient navigation services, personalized oncology pathways, and integrated supportive care frameworks. Organizations capable of improving healthcare affordability, treatment outcomes, and patient engagement are expected to strengthen long-term market competitiveness.

Conclusion

The global value-based oncology care market is expected to witness substantial growth due to rising cancer treatment costs, increasing adoption of alternative payment models, and growing emphasis on patient-centered healthcare delivery.

Advancements in precision oncology, healthcare analytics, AI-powered decision support systems, and digital care coordination technologies are significantly transforming oncology treatment frameworks. Healthcare systems increasingly prioritize outcome-driven reimbursement models capable of improving treatment quality while reducing overall healthcare expenditure.

The market continues to face challenges related to reimbursement complexity, interoperability limitations, regulatory uncertainty, and provider adaptation. However, ongoing healthcare modernization, expansion of evidence-based oncology pathways, and increasing payer-provider collaboration are expected to create substantial long-term growth opportunities for the value-based oncology care market.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Overview
  • 1.2 Key Insights
  • 1.3 Value-Based Care Adoption in Oncology - Snapshot
  • 1.4 Key Market Trends
  • 1.5 Analyst Recommendations

2. Disease & Epidemiology Analysis

  • 2.1 Global Cancer Burden Overview
    • 2.1.1 Incidence and Prevalence by Cancer Type
    • 2.1.2 Mortality Trends and Survival Rates
  • 2.2 Epidemiology by Key Indications
    • 2.2.1 Breast Cancer
    • 2.2.2 Lung Cancer
    • 2.2.3 Colorectal Cancer
    • 2.2.4 Prostate Cancer
    • 2.2.5 Hematologic Malignancies
  • 2.3 Economic Burden of Cancer Care
    • 2.3.1 Direct Medical Costs
    • 2.3.2 Indirect Costs and Productivity Loss
  • 2.4 Need for Value-Based Oncology Care Models

3. Value-Based Oncology Care Market Dynamics

  • 3.1 Market Definition and Scope
  • 3.2 Market Drivers
    • 3.2.1 Rising Cancer Incidence and Treatment Costs
    • 3.2.2 Shift from Fee-for-Service to Value-Based Models
    • 3.2.3 Increasing Adoption of Outcome-Based Reimbursement
  • 3.3 Market Restraints
    • 3.3.1 Complexity in Outcome Measurement
    • 3.3.2 Data Integration and Interoperability Challenges
    • 3.3.3 Limited Standardization in Value Metrics
  • 3.4 Market Opportunities
    • 3.4.1 Integration of Real-World Evidence (RWE)
    • 3.4.2 Digital Health and Oncology Data Platforms
    • 3.4.3 Expansion of Bundled Payment Models
  • 3.5 Market Challenges
    • 3.5.1 Provider Resistance and Workflow Disruptions
    • 3.5.2 Regulatory and Pricing Uncertainties

4. Commercial & Market Access

  • 4.1 Overview of Oncology Reimbursement Models
  • 4.2 Value-Based Payment Models in Oncology
    • 4.2.1 Bundled Payments
    • 4.2.2 Oncology Care Model (OCM) and Successor Models
    • 4.2.3 Accountable Care Organizations (ACOs)
    • 4.2.4 Pay-for-Performance Agreements
  • 4.3 Pricing Strategies in Value-Based Oncology
  • 4.4 Role of Payers and Providers
  • 4.5 Real-World Evidence in Market Access Decisions
  • 4.6 Health Technology Assessment (HTA) in Oncology

5. Innovation & Pipeline Landscape

  • 5.1 Role of Innovation in Value-Based Oncology Care
  • 5.2 Pipeline Overview by Modality
    • 5.2.1 Immunotherapies (Checkpoint Inhibitors, CAR-T)
    • 5.2.2 Targeted Therapies
    • 5.2.3 Radiopharmaceuticals
  • 5.3 Pipeline Analysis by Phase
    • 5.3.1 Phase I
    • 5.3.2 Phase II
    • 5.3.3 Phase III
  • 5.4 Mechanism of Action Trends
  • 5.5 Integration of Companion Diagnostics
  • 5.6 Digital Health Innovations Supporting Value-Based Care
    • 5.6.1 Clinical Decision Support Systems
    • 5.6.2 Remote Patient Monitoring
    • 5.6.3 AI in Oncology Pathways

6. Treatment Landscape

  • 6.1 Standard of Care by Cancer Type
  • 6.2 Role of Precision Medicine in Oncology
  • 6.3 Integration of Multidisciplinary Care Models
  • 6.4 Use of Biomarkers and Companion Diagnostics
  • 6.5 Treatment Pathways under Value-Based Models
  • 6.6 Outcomes Measurement in Oncology Care
    • 6.6.1 Clinical Outcomes
    • 6.6.2 Patient-Reported Outcomes (PROs)
    • 6.6.3 Quality-Adjusted Life Years (QALYs)

7. Value-Based Oncology Care Market Size & Forecast

  • 7.1 Global Market Size (Historical)
  • 7.2 Market Forecast (2026-2031)
  • 7.3 Growth Rate Analysis (CAGR)
  • 7.4 Market Share by Key Segments
  • 7.5 Scenario Analysis (Optimistic, Base, Conservative)

8. Value-Based Oncology Care Market Segmentation

  • 8.1 By Therapy Type
    • 8.1.1 Chemotherapy
    • 8.1.2 Targeted Therapy
    • 8.1.3 Immunotherapy
    • 8.1.4 Combination Therapy
  • 8.2 By Indication
    • 8.2.1 Breast Cancer
    • 8.2.2 Lung Cancer
    • 8.2.3 Colorectal Cancer
    • 8.2.4 Prostate Cancer
    • 8.2.5 Hematologic Malignancies
  • 8.3 By Route of Administration
    • 8.3.1 Oral
    • 8.3.2 Intravenous
    • 8.3.3 Subcutaneous
  • 8.4 By End User
    • 8.4.1 Hospitals
    • 8.4.2 Oncology Clinics
    • 8.4.3 Ambulatory Surgical Centers
  • 8.5 By Distribution Channel
    • 8.5.1 Hospital Pharmacies
    • 8.5.2 Retail Pharmacies
    • 8.5.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

  • 9.1 North America
    • 9.1.1 Market Size & Growth
    • 9.1.2 Key Demand Drivers
    • 9.1.3 Regulatory Overview
    • 9.1.4 Competitive Intensity
  • 9.2 Europe
    • 9.2.1 Market Size & Growth
    • 9.2.2 Key Demand Drivers
    • 9.2.3 Regulatory Overview
    • 9.2.4 Competitive Intensity
  • 9.3 Asia-Pacific
    • 9.3.1 Market Size & Growth
    • 9.3.2 Key Demand Drivers
    • 9.3.3 Regulatory Overview
    • 9.3.4 Competitive Intensity
  • 9.4 Latin America
    • 9.4.1 Market Size & Growth
    • 9.4.2 Key Demand Drivers
    • 9.4.3 Regulatory Overview
    • 9.4.4 Competitive Intensity
  • 9.5 Middle East & Africa
    • 9.5.1 Market Size & Growth
    • 9.5.2 Key Demand Drivers
    • 9.5.3 Regulatory Overview
    • 9.5.4 Competitive Intensity

10. Key Countries Analysis

  • 10.1 United States
    • 10.1.1 Market Size
    • 10.1.2 Cancer Epidemiology
    • 10.1.3 Regulatory Framework (FDA)
    • 10.1.4 Reimbursement Landscape
    • 10.1.5 Key Companies and Product Presence
  • 10.2 Canada
    • 10.2.1 Market Size
    • 10.2.2 Epidemiology
    • 10.2.3 Regulatory Framework
    • 10.2.4 Reimbursement
    • 10.2.5 Key Players
  • 10.3 Germany
    • 10.3.1 Market Size
    • 10.3.2 Epidemiology
    • 10.3.3 Regulatory Framework
    • 10.3.4 Reimbursement
    • 10.3.5 Key Players
  • 10.4 United Kingdom
    • 10.4.1 Market Size
    • 10.4.2 Epidemiology
    • 10.4.3 Regulatory Framework
    • 10.4.4 Reimbursement
    • 10.4.5 Key Players
  • 10.5 France
    • 10.5.1 Market Size
    • 10.5.2 Epidemiology
    • 10.5.3 Regulatory Framework
    • 10.5.4 Reimbursement
    • 10.5.5 Key Players
  • 10.6 Italy
    • 10.6.1 Market Size
    • 10.6.2 Epidemiology
    • 10.6.3 Regulatory Framework
    • 10.6.4 Reimbursement
    • 10.6.5 Key Players
  • 10.7 Spain
    • 10.7.1 Market Size
    • 10.7.2 Epidemiology
    • 10.7.3 Regulatory Framework
    • 10.7.4 Reimbursement
    • 10.7.5 Key Players
  • 10.8 China
    • 10.8.1 Market Size
    • 10.8.2 Epidemiology
    • 10.8.3 Regulatory Framework (NMPA)
    • 10.8.4 Reimbursement
    • 10.8.5 Key Players
  • 10.9 Japan
    • 10.9.1 Market Size
    • 10.9.2 Epidemiology
    • 10.9.3 Regulatory Framework (PMDA)
    • 10.9.4 Reimbursement
    • 10.9.5 Key Players
  • 10.10 India
    • 10.10.1 Market Size
    • 10.10.2 Epidemiology
    • 10.10.3 Regulatory Framework (CDSCO)
    • 10.10.4 Reimbursement
    • 10.10.5 Key Players
  • 10.11 South Korea
    • 10.11.1 Market Size
    • 10.11.2 Epidemiology
    • 10.11.3 Regulatory Framework
    • 10.11.4 Reimbursement
    • 10.11.5 Key Players
  • 10.12 Australia
    • 10.12.1 Market Size
    • 10.12.2 Epidemiology
    • 10.12.3 Regulatory Framework
    • 10.12.4 Reimbursement
    • 10.12.5 Key Players
  • 10.13 Brazil
    • 10.13.1 Market Size
    • 10.13.2 Epidemiology
    • 10.13.3 Regulatory Framework
    • 10.13.4 Reimbursement
    • 10.13.5 Key Players
  • 10.14 Mexico
    • 10.14.1 Market Size
    • 10.14.2 Epidemiology
    • 10.14.3 Regulatory Framework
    • 10.14.4 Reimbursement
    • 10.14.5 Key Players
  • 10.15 Saudi Arabia
    • 10.15.1 Market Size
    • 10.15.2 Epidemiology
    • 10.15.3 Regulatory Framework
    • 10.15.4 Reimbursement
    • 10.15.5 Key Players
  • 10.16 South Africa
    • 10.16.1 Market Size
    • 10.16.2 Epidemiology
    • 10.16.3 Regulatory Framework
    • 10.16.4 Reimbursement
    • 10.16.5 Key Players

11. Regulatory & Policy Landscape

  • 11.1 United States (FDA)
    • 11.1.1 Value-Based Care Policies
    • 11.1.2 Oncology-Specific Payment Models
  • 11.2 Europe (EMA and MDR Framework)
    • 11.2.1 HTA and Pricing Regulations
    • 11.2.2 Value-Based Agreements
  • 11.3 Japan (PMDA)
    • 11.3.1 Pricing and Reimbursement Policies
  • 11.4 India (CDSCO)
    • 11.4.1 Pricing Controls and Access Programs
  • 11.5 China (NMPA)
    • 11.5.1 Volume-Based Procurement and Pricing
  • 11.6 Global Policy Trends in Value-Based Oncology

12. Competitive Landscape

  • 12.1 Market Structure Analysis
  • 12.2 Key Strategic Initiatives
    • 12.2.1 Partnerships and Collaborations
    • 12.2.2 Mergers and Acquisitions
    • 12.2.3 Value-Based Contracting Agreements
  • 12.3 Market Share Analysis (Indicative)
  • 12.4 Competitive Benchmarking

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
    • 13.1.1 Approved Products
    • 13.1.2 Key Indications
    • 13.1.3 Pipeline Overview
  • 13.2 Merck & Co., Inc.
    • 13.2.1 Approved Products
    • 13.2.2 Key Indications
    • 13.2.3 Pipeline Overview
  • 13.3 Bristol-Myers Squibb Company
    • 13.3.1 Approved Products
    • 13.3.2 Key Indications
    • 13.3.3 Pipeline Overview
  • 13.4 Pfizer Inc.
    • 13.4.1 Approved Products
    • 13.4.2 Key Indications
    • 13.4.3 Pipeline Overview
  • 13.5 Novartis AG
    • 13.5.1 Approved Products
    • 13.5.2 Key Indications
    • 13.5.3 Pipeline Overview
  • 13.6 AstraZeneca PLC
    • 13.6.1 Approved Products
    • 13.6.2 Key Indications
    • 13.6.3 Pipeline Overview
  • 13.7 Johnson & Johnson
    • 13.7.1 Approved Products
    • 13.7.2 Key Indications
    • 13.7.3 Pipeline Overview

13.8Amgen

    • 13.8.1 Approved Products
    • 13.8.2 Key Indications
    • 13.8.3 Pipeline Overview

13.9Gilead Sciences

    • 13.9.1 Approved Products
    • 13.9.2 Key Indications
    • 13.9.3 Pipeline Overview

14. Future Outlook

  • 14.1 Evolution of Value-Based Oncology Models
  • 14.2 Integration of AI and Big Data
  • 14.3 Shift Toward Personalized and Outcome-Driven Care
  • 14.4 Long-Term Market Opportunities
  • 14.5 Strategic Recommendations

15. Methodology

  • 15.1 Research Design
  • 15.2 Data Collection Sources
  • 15.3 Market Estimation Techniques
  • 15.4 Forecasting Methodology
  • 15.5 Assumptions and Limitations